The frontline standard-of-care regimen for patients with higher-risk MDS and some with lower-risk MDS remain hypomethylating agents, such as azacitidine, decitabine, and decitabine/cedazuridine.
Kelly Chien, MD
Advertisement
Kelly Chien, MD, is an assistant Professor in the department of leukemia, division of cancer medicine, The University of Texas MD Anderson Cancer Center, in Houston, TX.
Articles by Kelly Chien, MD
Advertisement
Latest Updated Articles
Addressing MDS Treatment Gap Post Hypomethylating FailurePublished: March 21st 2024 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
